Tests VMAC with donor lymphocyte infusion for leukemia that returned after transplant
Tests VMAC with donor lymphocyte infusion in adults with acute myeloid leukemia relapsed after transplant.
Plain-language title generated from the registry record
Registry title: VMAC+DLI Treatment of Patients With Relapse of AML After Allo-HSCT
Key facts
- Where
- Tianjin, ChinaSee the site
- Phase
- Phase 2
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with acute myeloid leukemia (AML) that came back after a stem-cell transplant from a donor. It tests VMAC treatment together with donor lymphocyte infusion (DLI).
- Age
- 18 to 65 years
- Sex
- All sexes can join.
- Disease stage
- AML that came back after a donor stem-cell transplant (allo-HSCT), with 5% or more blast cells in the bone marrow. Daily activity level (ECOG) of 0-2.
- Earlier treatment
- A donor stem-cell transplant (allo-HSCT) before. People who had a second transplant cannot join.
Main reasons for not taking part
- Second transplant
- Transplant from an unrelated donor
- HIV, active hepatitis B or C, or syphilis
- Pregnancy, or not able to use proper contraception during treatment
- Active heart disease
Read by machine on 12 November 2026.
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 65 years old?
Source: NCT06447090, who can take part
Where in China
- Institute of Hematology & Blood Diseases Hospital, ChinaTianjin, ChinaContact: Xin Chen, DoctorTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Institute of Hematology & Blood Diseases Hospital, China
- Trial code
- NCT06447090
- Record updated
- 6 June 2024
- Original description
This clinical trial included 30 cases and aimed to understand the effectiveness and safety of the VMAC regimen combined with donor lymphocyte infusion (DLI) in the treatment of patients with acute myeloid leukemia who have relapsed after allogeneic hematopoietic stem cell transplantation.Read full original descriptionShow less
Study on the Efficacy and Safety of VMAC Combined With Donor Lymphocyte Infusion (DLI) in the Treatment of Patients With Relapse of Acute Myeloid Leukemia After Allogeneic Hematopoietic Stem Cell Transplantation
This clinical trial included 30 cases and aimed to understand the effectiveness and safety of the VMAC regimen combined with donor lymphocyte infusion (DLI) in the treatment of patients with acute myeloid leukemia who have relapsed after allogeneic hematopoietic stem cell transplantation.
The main questions it aims to answer are:
The safety and efficacy of VMAC combined with DLI in the treatment of allo HSCT recurrence in AML patients;
Inclusion: Patients with AML confirmed by bone marrow morphology and morphological recurrence after allo-HSCT (proportion of bone marrow morphological blast cells ≥5%); Age ≥18 years and ≤65 years old, regardless of gender; Eastern Oncology The evaluation of physical status of the cooperative group (ECOG-PS) is 0-2 points; An informed consent form must be signed before the start of the research procedure, and the patient himself or his immediate family members must sign the informed consent form. Considering the patient's condition, if the patient's signature is not conducive to the treatment of the condition, the legal guardian or the patient's immediate family member will sign the informed consent form.
Exclusion: 1) Secondary transplant patients; 2) Have a history of tumor and have received any treatment for this tumor in the past 3 years, except for superficial bladder cancer , basal cell or squamous cell carcinoma of the skin, cervical intraepithelial carcinoma (CIN) or prostate intraepithelial carcinoma (PIN); 7) Transplantation from an unrelated donor; 3) Serological reactions of known HIV, active hepatitis B, and active hepatitis C virus positive or syphilis positive; 4) Suffering from mental illness or other conditions and unable to cooperate with the requirements of research treatment and monitoring; 6) Active heart disease, definition One or more of the following:; Long QTc syndrome or QTc interval >480ms; Complete left bundle branch block, II or III degree atrioventricular block; Need for drug treatment or History of severe arrhythmia with clinical symptoms; New York Heart Association classification ≥ II; Left ventricular ejection fraction less than 50%; Myocardial infarction, unstable angina, severe myocardial infarction within 6 months before enrollment History of unstable ventricular arrhythmias or any other arrhythmias requiring treatment, clinically severe pericardial disease, or electrocardiographic evidence of acute ischemia or active conduction system abnormalities; Subjects who meet any of the following criteria shall not be enrolled in this study:; 5) Pregnant patients or patients who cannot take appropriate contraceptive measures during treatment; 8) Those deemed not suitable for enrollment by the researcher.